文献速递前列腺癌

中危前列腺癌主动监测的应用趋势与差异

Active Surveillance for Men with Intermediate Risk Prostate Cancer.
PubMed 文献 · J Urol · 2020-07-13

该回顾性队列研究分析了2010至2016年美国国家癌症数据库中176,122例中危前列腺癌男性,发现主动监测使用率从1.6%增至4.6%(p<0.001),但仅占3.2%,且与年龄、诊断年份、Gleason评分、保险类型、学术中心及教育程度相关。

要点

  • 中危前列腺癌主动监测使用率从2010年1.6%升至2016年4.6%,仍处低位。
  • 主动监测与高龄、近期诊断、低Gleason评分和分期、学术中心治疗等相关。
  • 种族和合并症与主动监测使用无关。

核心结论

  • 中危前列腺癌主动监测使用率虽近三倍增长,但整体仍低,且存在临床和社会经济差异。

研究设计与样本

  • 回顾性队列研究,纳入2010至2016年美国国家癌症数据库176,122例中危前列腺癌男性。
  • 分析人口学、临床和社会经济因素与主动监测使用的关联,分析于2020年4月进行。

主要发现

  • 57.3%接受前列腺切除术,36.4%接受放疗,3.2%接受主动监测。
  • 主动监测使用率从2010年1.6%升至2016年4.6%(p<0.001)。
  • 多变量分析显示主动监测与高龄、近期诊断、较低Gleason评分和肿瘤分期、保险类型、学术中心治疗及距离设施近、高教育程度相关(p<0.05)。
  • 种族和合并症与主动监测无关。

临床怎么用

  • 临床决策中需注意中危前列腺癌主动监测使用存在差异,应结合风险分层个体化选择。

局限性

  • 回顾性设计,需前瞻性数据和改进的风险分层来指导中危前列腺癌的最佳治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Optimal treatment of intermediate risk prostate cancer remains unclear. National Comprehensive Cancer Network® guidelines recommend active surveillance, prostatectomy or radiotherapy. Recent trials demonstrated no difference in prostate cancer specific mortality for men undergoing active surveillance for low risk prostate cancer compared to prostatectomy or radiotherapy. The use of active surveillance for intermediate risk prostate cancer is less clear. In this study we characterize U.S. national trends for demographic, clinical and socioeconomic factors associated with active surveillance for men with intermediate risk prostate cancer. MATERIALS AND METHODS: This retrospective cohort study examined 176,122 men diagnosed with intermediate risk prostate cancer from 2010 to 2016 in the National Cancer Database. Temporal trends in demographic, clinical and socioeconomic factors among men with intermediate risk prostate cancer and association with the use of active surveillance were characterized. The analysis was performed in April 2020. RESULTS: In total, 176,122 men were identified with intermediate risk prostate cancer from 2010 to 2016. Of these men 57.3% underwent prostatectomy, 36.4% underwent radiotherapy and 3.2% underwent active surveillance. Active surveillance nearly tripled from 1.6% in 2010 to 4.6% in 2016 (p <0.001). On multivariate analysis use of active surveillance was associated with older age, diagnosis in recent years, lower Gleason score and tumor stage, type of insurance, treatment at an academic center and proximity to facility, and attaining higher education (p <0.05). Race and comorbidities were not associated with active surveillance. CONCLUSIONS: Our findings highlight increasing active surveillance use for men with intermediate risk prostate cancer demonstrating clinical and socioeconomic disparities. Prospective data and improved risk stratification are needed to guide optimal treatment for men with intermediate risk prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Agrawal V, Ma X, Hu JC, et al. Active Surveillance for Men with Intermediate Risk Prostate Cancer. J Urol. 2020. PMID: 32658588. doi:10.1097/JU.0000000000001241

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。